AL
CARM

Airain Ltd’s Carisma Therapeutics CARM Stock Holding History

Airain Ltd’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,258
Closed -$48K – 815
2016
Q4 		$48K Buy
1,258
+604
+92% +$26.6K ﹤0.01% 639
2016
Q3 		$37K Buy
+654
New +$48.7K ﹤0.01% 583
2015
Q4 		– Sell
-878
Closed -$42K – 850
2015
Q3 		$42K Buy
+878
New +$54.1K ﹤0.01% 798

Other funds holding CARM

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EGA
Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return

Airain Ltd's CARM Position: Q1 2017 in Review

Airain Ltd sold out of Carisma Therapeutics (CARM) in Q1 2017, closing a stake of 1,258 shares — an estimated $48K sold.

Airain Ltd first reported a position in CARM in Q3 2015 and held it in 3 quarters. The position peaked at $48K in Q4 2016. 27 funds tracked by Wall St. Rank hold CARM as of Q1 2017.

  • Airain Ltd reported no remaining Carisma Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Airain Ltd sold 1,258 Carisma Therapeutics shares in Q1 2017, an estimated $48K.
  • Airain Ltd first reported a position in Carisma Therapeutics in Q3 2015 and held it in 3 quarters.
  • Airain Ltd's Carisma Therapeutics position peaked at $48K in Q4 2016.
  • 27 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2017.

Based on Airain Ltd's 13F filing for Q1 2017, filed 9 May 2017.